dolutegravir sodium; lamivudine · Viiv Hlthcare · NDA 211994
Dovato
Earliest generic entry, as listed
24 Jan 2031
Blocked by patent: US 11234985.
Listed patents · 3 unexpired
5 Orange Book listing rows for 3 patents, including 2 pediatric extensions. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.
| Patent | Claims | Expires |
|---|---|---|
| US 11234985 | drug product, use U-257 · sets the listed date | 24 Jan 2031 |
| US 9242986 | drug substance, drug product | 8 Jun 2030 |
| US 9242986 listing row | drug substance, drug product | 8 Dec 2029 |
| US 9242986 listing row | pediatric extension | 8 Jun 2030 |
| US 8129385 | drug substance, drug product | 5 Apr 2028 |
| US 8129385 listing row | drug substance, drug product | 5 Oct 2027 |
| US 8129385 listing row | pediatric extension | 5 Apr 2028 |
Exclusivities · 1 unexpired
| NPP | new patient population | 5 Apr 2027 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 211994 · 001 · RLD | tablet, oral | EQ 50MG BASE;300MG | 24 Jan 2031 |